日本語  English

遺伝子治療用脂肪細胞関連業績

遺伝子治療用脂肪細胞論文一覧

英文原著

  1. Kuroda M, Holleboom AG, Stroes E, Asada S, Aoyagi Y, Kamata K, Yamashita S, Ishibashi S, Saito Y, Bujo H. (2014)　Lipoprotein subfractions highly associated with renal damage in familial LCAT deficiency Arterioscler Thromb Vasc Biol. 34, 1756-1762.
  2. Naito S, Kamata M, Furuya M, Hayashi M, Kuroda M, Bujo H, Kamata K. (2013) Amelioration of circulating lipoprotein profile and proteinuria in a patient with LCAT deficiency due to a novel mutation (Cys74Tyr) in the lid region of LCAT under a fat-restricted diet and ARB treatment. Atherosclerosis. 228, 193-197.
  3. Fukaya Y, Kuroda M, Aoyagi Y, Asada S, Kubota Y, Okamoto Y, Nakayama T, Saito Y, Satoh K, Bujo H. (2012) Platelet-rich plasma inhibits the apoptosis of highly adipogenic homogeneous preadipocytes in an in vitro culture system. Exp. Mol. Med. 44, 330-339.
  4. Aoyagi Y, Kuroda M, Asada S, Tanaka S, Konno S, Tanio M, Aso M, Okamoto Y, Nakayama T, Saito Y, Bujo H. (2012) Fibrin glue is a candidate scaffold for long-term therapeutic protein expression in spontaneously differentiated adipocytes in vitro. Exp Cell Res. 318, 8-15.
  5. Kuroda M, Bujo H, Aso M, Saito, Y. (2011) Adipocytes as a vehicle for ex vivo gene therapy: Novel replacement therapy for diabetes and other metabolic diseases. J. Diabetes Invest. 2, 333-340.
  6. Asada S, Kuroda M, Aoyagi Y, Fukaya Y, Tanaka S, Konno S, Tanio M, Aso M, Satoh K, Okamoto Y, Nakayama T, Saito Y, Bujo H. (2011) Ceiling culture-derived proliferative adipocytes retain high adipogenic potential suitable for use as a vehicle for gene transduction therapy. Am. J. Physiol. Cell Physiol. 301, C181-C185.
  7. Aoyagi Y, Kuroda M, Asada S, Bujo H, Tanaka S, Konno S, Tanio M, Ishii I, Aso M, Saito Y. (2011) Fibrin glue increases the cell survival and the transduced gene product secretion of the ceiling culture-derived adipocytes transplanted in mice. Exp. Mol. Med. 43, 161-167.
  8. Kuroda M, Aoyagi Y, Asada S, Bujo H, Tanaka S, Konno S, Tanio M, Ishii I, Machida K, Matsumoto F, Satoh K, Aso M, Saito Y. (2011) Ceiling culture-derived proliferative adipocytes are a possible delivery vehicle in enzyme replacement therapy in lecithin:cholesterol acyltransferase deficiency. Open Gene Ther. J. 4, 1-10.
  9. Asada S, Kuroda M, Aoyagi Y, Bujo H, Tanaka S, Konno S, Tanio M, Ishii I, Aso M, Saito Y. (2011) Disturbed apolipoprotein A-I-containing lipoproteins in fish-eye disease are improved by the lecithin:cholesterol acyltransferase produced by gene-transduced adipocytes in vitro. Mol. Genet. Metab. 102, 229-231.
  10. Ito M, Bujo H, Takahashi K, Arai T, Tanaka I, Saito Y. (2005) Implantation of primary cultured adipocytes that secrete insulin modifies blood glucose levels in diabetic mice. Diabetologia. 48, 1614-1620.

邦文総説、著書

  1. 黒田正幸、武城英明、齋藤康、横手幸太郎. 遺伝的酵素欠損症に対する遺伝子・細胞治療. 内分泌疾患のtrends & topics 2016. 月刊Mebio. メジカルレビュー社、2016.33.75-82.
  2. 黒田正幸、横手幸太郎. 遺伝子導入脂肪細胞の移植による持続的酵素補充療法-家族性LCAT 欠損症を対象とした治療法開発と難治性疾患への応用展開-,再生医療等製品の開発と実用化展望 第16章; p123-130、シーエムシー出版、2016年6月発行
  3. 黒田正幸、武城英明、麻生雅是、齋藤康、横手幸太郎. 疾患治療用タンパク質分泌加工脂肪細胞の創薬開発と難病治療. 薬学雑誌-Symposium Review- 2016, 136; 705-709.
  4. 黒田正幸、武城英明. 脂質異常症の遺伝子細胞治療－LCAT欠損症患者への新規治療法の開発－, Annual Review 糖尿病・代謝・内分泌2015（寺内康夫・伊藤裕・石橋俊 編集）、中外医学社、発刊日 2015/1/30
  5. 黒田正幸、武城英明. LCAT欠損症の診断と治療, 腎と透析、2014, 77; 226-230.
  6. 麻生雅是、黒田正幸. ヒト脂肪細胞の初代分離・培養と臨床応用, Organ Biology、2014, 21; 60-65.
  7. 黒田正幸、武城英明. 家族性LCAT欠損症, 先天代謝異常ハンドブック（遠藤文夫他 編集）、中山書店、発刊日2013/2/20
  8. 黒田正幸、武城英明. 家族性LCAT欠損症, 日本臨牀増刊、脂質異常症、　2013, 71; 275-279.
  9. 黒田正幸、武城英明. 脂質異常症の遺伝子治療, Curr Ther. 2012;30:264-265
  10. 黒田正幸、武城英明 (2010) 脂肪細胞による新規蛋白質補充療法－LCAT欠損症遺伝子治療臨床研究－医学のあゆみ233, 1246-1247.